A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers
Background: MMRpro, prediction of mutations in MLH1 and MLH2 (PREMM1,2) and MMRpredict are models which were developed to predict the probability that an individual carries a Lynch syndrome-causing mutation. Each model utilizes data from personal and family histories of cancer. To date, no studies h...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 2009-04, Vol.20 (4), p.681-688 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: MMRpro, prediction of mutations in MLH1 and MLH2 (PREMM1,2) and MMRpredict are models which were developed to predict the probability that an individual carries a Lynch syndrome-causing mutation. Each model utilizes data from personal and family histories of cancer. To date, no studies have compared these models in a cancer genetics clinic. The purpose of this study was to determine each model's ability to predict the probability of carrying a Lynch syndrome-causing mutation in individuals with a family history of colorectal cancer and to determine their clinical applicability. Methods: We obtained family pedigrees from 81 individuals who presented for Lynch syndrome testing due to a personal and/or family history of cancer. Data from each pedigree were entered into the models and analyzed using SPSS. Results: We found that MMRpredict, PREMM1,2 and MMRpro showed similar performances with areas under the receiver-operating characteristic curve of 0.731, 0.765 and 0.732, respectively. MMRpro showed the least dispersion of mutation probability estimates with a P value of 0.205, compared with 0.034 for PREMM1,2 and 0.001 for MMRpredict. Conclusion: We found all three carried out well in a cancer genetics setting, with PREMM1,2 giving slightly better estimates. There were some significant discrepancies between the models in cases where the proband had endometrial cancer. |
---|---|
ISSN: | 0923-7534 1569-8041 |
DOI: | 10.1093/annonc/mdn686 |